Bausch Health Companies | VRX - Assets


Bausch Health Companies reported $25.48B in Assets for its fiscal quarter ending in September of 2026.





Assets Change Date
Amgen USD 96.05B 409M Sep/2026
ANI Pharmaceuticals USD 1.57B 73.55M Sep/2026
Aurora Cannabis CAD 620.88M 19.79M Jun/2026
Bausch Health Companies USD 25.48B 690M Sep/2026
Biogen USD 32.05B 32.5M Sep/2026
Bristol-Myers Squibb USD 88.77B 1.14B Sep/2026
Canopy Growth CAD 1.1B 14.81M Jun/2026
Corcept Therapeutics USD 1.03B 145.32M Sep/2026
Danaher USD 93.28B 914M Sep/2026
Drreddys Laboratories INR 574.48B 4.86B Sep/2026
Eli Lilly USD 148.07B 5.79B Sep/2026
Gilead Sciences USD 51.41B 2.05B Sep/2026
Nektar Therapeutics USD 763.27M 482.86M Mar/2026
Novo Nordisk DKK 594.94B 35.72B Jun/2026
Pacira USD 34.68B 33.44B Sep/2026
Perrigo USD 7.48B 124.6M Sep/2026
Phibro Animal Health USD 1.51B 13.48M Sep/2026
Prestige Brands USD 4.72B 153.09M Sep/2026
Supernus Pharmaceuticals USD 1.4B 30.42M Sep/2026
Vertex Pharmaceuticals USD 32.74B 5.31B Sep/2026
Zoetis USD 15.09B 11M Sep/2026